P/E at 30.44 vs Industry's 36.64: What the Data Shows for Dr Reddys Laboratories Ltd

Valuation Picture: Discount to Industry Average

The current P/E ratio of Dr Reddys Laboratories Ltd at 30.44 represents a discount of approximately 17% relative to the sector average of 36.64. This valuation gap suggests the market is pricing in either subdued growth expectations or elevated risks compared to peers. Given the mid-cap status with a market capitalisation of ₹98,074 crores, the stock’s valuation is somewhat conservative within its sector, which often commands premium multiples due to robust earnings growth and innovation pipelines. Dr Reddys Laboratories Ltd’s discount could reflect recent performance challenges or sector rotation effects, but is this valuation gap signalling a buying opportunity or a justified caution?

Performance Across Timeframes: Divergent Momentum

Examining the stock’s returns across multiple horizons reveals a nuanced picture. Over the past year, Dr Reddys Laboratories Ltd has declined by 8.22%, underperforming the Sensex’s 4.38% loss. The short-term trend is more concerning: the stock has fallen 10.34% in the last three months while the Sensex gained 3.09%. This divergence indicates recent headwinds that have intensified, possibly linked to sector-specific challenges or company-level developments. Conversely, the one-month return of 1.68% slightly lags the Sensex’s 2.22%, and the year-to-date return of -7.79% is marginally better than the Sensex’s -8.77%, suggesting some resilience amid broader market weakness. What factors are driving this short-term underperformance despite a relatively stable longer-term trend?

Moving Average Configuration: Mixed Technical Signals

The technical setup for Dr Reddys Laboratories Ltd is characterised by a mixed moving average configuration. The stock price currently sits above the 20-day moving average but remains below the 5-day, 50-day, 100-day, and 200-day moving averages. This pattern suggests a tentative recovery attempt within a broader downtrend. The fact that the price is above the 20-day MA but below the longer-term averages indicates short-term buying interest that has yet to translate into sustained momentum. The stock has also experienced a consecutive two-day decline, losing 0.84% in that period, and underperformed its sector by 0.55% today. Is this a genuine recovery or a dead-cat bounce? — the moving average configuration provides the clearest answer.

Relative Performance vs Sensex: Lagging in Most Periods

When compared to the Sensex, Dr Reddys Laboratories Ltd has underperformed across most timeframes. The one-year return of -8.22% contrasts with the Sensex’s -4.38%, and the three-month return of -10.34% is particularly weak against the Sensex’s positive 3.09%. Even the one-week performance shows a decline of 1.68% versus a flat 0.02% for the Sensex. Longer-term returns also lag behind: the three-year return is -0.73% compared to the Sensex’s 19.15%, and the five-year return of 27.73% trails the Sensex’s 38.93%. The ten-year return of 92.82% is less than half the Sensex’s 177.07%, highlighting a persistent underperformance trend. Should investors in Dr Reddys Laboratories Ltd hold, buy more, or reconsider?

Sector Performance Context: Mixed Results in Pharmaceuticals & Biotechnology

The Pharmaceuticals & Biotechnology sector has seen mixed results in recent earnings announcements. Out of 34 stocks that declared results, 14 reported positive outcomes, 15 were flat, and 5 posted negative results. This distribution indicates a broadly cautious environment with no clear sector-wide momentum. Dr Reddys Laboratories Ltd’s recent underperformance aligns with this cautious sector backdrop, though the stock’s valuation discount suggests some differentiation from peers. How does this sector performance influence the stock’s outlook?

Rating Reassessment: Previously Hold, Now Updated

MarketsMOJO previously rated Dr Reddys Laboratories Ltd as Hold. The rating was reassessed on 13 Jul 2026, reflecting the evolving data landscape. The current Mojo Score stands at 30.0, with a Mojo Grade of Sell. This change underscores the impact of recent performance trends and valuation considerations. The rating update invites investors to reanalyse the stock’s position within their portfolios, especially given the mixed technical signals and relative underperformance. What is the current rating for Dr Reddys Laboratories Ltd following this reassessment?

Conclusion: A Complex Data-Driven Picture

The data on Dr Reddys Laboratories Ltd paints a multifaceted picture. The stock trades at a valuation discount to its sector, reflecting tempered market expectations. Performance metrics reveal underperformance relative to the Sensex across most timeframes, with a particularly sharp decline over the past three months. The moving average configuration suggests a tentative short-term recovery within a longer-term downtrend. Sector results are mixed, adding to the cautious tone. The recent rating reassessment from Hold to a different grade signals a shift in the stock’s risk-reward profile. Collectively, these factors highlight the importance of a nuanced approach to analysing Dr Reddys Laboratories Ltd — should investors reconsider their stance in light of these data points?

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →